🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Shanghai Fosun Pharmaceutical Industrial Development clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Shanghai Fosun Pharmaceutical Industrial Development as lead sponsor. Synced 26 Sep 2026
16Current trials
3Recruiting now
5Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Shanghai Fosun Pharmaceutical Industrial Development is the lead sponsor of 16 current clinical trials in our China and USA registers. 3 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Luvometinib, FCN-159 and FXS6837. The most-studied condition is Neurofibromatosis 1.

ClinicalTrials.gov trials by status

  • Recruiting319%
  • Not yet open956%
  • Active, closed425%

Trials by phase

  • Phase 2638%
  • Phase 1425%
  • Phase 3425%
  • Phase 1/2213%
01

Clinical trials sponsored by Shanghai Fosun Pharmaceutical Industrial Development

16 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC
NCT07562581 · ClinicalTrials.gov ↗ · Non-small Cell Lung Caner, KRAS-mutated, Metastasis
Phase 2 Recruiting 2026-06 China
A Phase II Clinical Trial to Evaluate the Efficacy and Safety of FXS5626 in Patients With NIU
NCT07552012 · ClinicalTrials.gov ↗ · Active Non-anterior, Non-infectious Uveitis
Phase 2 Recruiting 2026-01 China
To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
NCT05997602 · ClinicalTrials.gov ↗ · Langerhans Cell Histiocytosis, LCH
Drug: FCN-159
Phase 2 Recruiting 2023-09 China
Phase I Study of FXS887 in the Treatment of Solid Tumors
NCT07345637 · ClinicalTrials.gov ↗ · Solid Tumor Refractory to Conventional Treatment
Phase 1 Not yet open 2026-01 China
QT Interval Effects Study of Oral FXS5626 Tablets
NCT07695779 · ClinicalTrials.gov ↗ · Evaluation of QTc Interval
Phase 1 Not yet open 2026-08 China
A Study of the Efficacy and Safety of FXS6837 Capsules Compared to Eculizumab for 24 Weeks in Patients With PNH.
NCT07747090 · ClinicalTrials.gov ↗ · Paroxysmal Nocturnal Hemoglobinuria
Phase 3 Not yet open 2026-12 China
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
NCT07024394 · ClinicalTrials.gov ↗ · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Phase 1/2 Not yet open 2025-06 China
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089 · ClinicalTrials.gov ↗ · B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes
Phase 1 Not yet open 2026-06 China
FXS6837 for the Treatment of IgAN Patients
NCT07502638 · ClinicalTrials.gov ↗ · IgAN
Phase 2 Not yet open 2026-03 China
FXS6837 for the Treatment for IgAN Patients(Longterm Study)
NCT07750665 · ClinicalTrials.gov ↗ · Primary IgAN
Drug: FXS6837
Phase 2 Not yet open 2026-09 China
FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration
NCT07004075 · ClinicalTrials.gov ↗ · Low-grade Glioma, Pediatric Low-grade Gliomas, pLGG With BRAF Alteration
Phase 3 Not yet open 2025-06 China
Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors
NCT07558200 · ClinicalTrials.gov ↗ · Solid Tumors, Non-Small Cell Lung Cancer, Hepatocellular Carcinoma
Phase 1 Not yet open 2026-05 China
Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC
NCT06569420 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, ALK-positive, SAF-189s
Phase 3 Active, closed 2021-12 China
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
NCT04954001 · ClinicalTrials.gov ↗ · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Drug: FCN-159
Phase 1/2 Active, closed 2021-03 USA, China
FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms
NCT06858618 · ClinicalTrials.gov ↗ · Safety, Antitumor Activity, PK Profile
Phase 2 Active, closed 2023-08 China
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
NCT05913037 · ClinicalTrials.gov ↗ · Neurofibromatosis 1, Plexiform Neurofibroma, NF1
Phase 3 Active, closed 2023-06 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Shanghai Fosun Pharmaceutical Industrial Development trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Shanghai Fosun Pharmaceutical Industrial Development trials

30 conditions
Neurofibromatosis 13Plexiform Neurofibroma3NF13Non-Small Cell Lung Cancer2Solid Tumor Refractory to Conventional Treatment1ALK-positive1SAF-189s1Evaluation of QTc Interval1Paroxysmal Nocturnal Hemoglobinuria1Non-small Cell Lung Caner1KRAS-mutated1Metastasis1Previous Treamted1B-Cell Lymphoma1Acute Myeloid Leukemia1Myelodysplastic Syndromes1Acute Lymphoblastic Leukemia1Safety1Antitumor Activity1PK Profile1Active Non-anterior, Non-infectious Uveitis1IgAN1Primary IgAN1Langerhans Cell Histiocytosis1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China163
Clinical trials in USA10

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Neurofibromatosis 1

SponsorTrials
Shanghai Kechow Pharma1

Sponsors with the most current trials registered for this condition.

06

Questions about Shanghai Fosun Pharmaceutical Industrial Development trials

How many clinical trials does Shanghai Fosun Pharmaceutical Industrial Development sponsor?

Shanghai Fosun Pharmaceutical Industrial Development is the lead sponsor of 16 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Shanghai Fosun Pharmaceutical Industrial Development trials recruiting?

Yes. 3 of its 16 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Shanghai Fosun Pharmaceutical Industrial Development testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Luvometinib (3), FCN-159 (2), FXS6837 (2), Anlotinib (1) and Eculizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.